Results of Three Studies Indicate 17-Gene Assay Is a Significant Predictor of Prostate Cancer Aggressiveness at the Time of Diagnosis

“According to the results from three studies published in European Urology, the 17-gene Oncotype DX Genomic Prostate Score is a significant predictor of disease aggressiveness at the time of diagnosis before intervention with radiation or surgery. The test provides more precise and individualized risk assessment than currently available tools and may help physicians choose the most appropriate treatment for their patients.”

Editor’s note: Newly diagnosed prostate cancer patients face complex treatment decisions based on many different factors. One major consideration is the level of aggressiveness of the cancer, i.e. how fast the cancer is likely to grow and metastasize. A test called the Oncotype DX Genomic Prostate Score examines 17 tumor genes to determine aggressiveness, and new research results show that the test is effective. Learn more about the test.


PTEN Breakthrough Could Lead to More Effective Targeted Therapies

For a long time, researchers have been investigating PTEN, a tumor suppressor gene that is mutated or missing in close to half of all advanced cancers. Without a healthy, functioning PTEN gene, cancer can become endlessly surviving, allowing tumors to grow and spread quickly and more aggressively. Recent research has determined that a new wave of drugs could begin to target PTEN-deficient cells. Researchers report that certain drugs act to make these cells, which previously had been totally resistant to treatment, vulnerable to chemotherapy and radiation. Following up with chemotherapy and radiotherapy sessions could therefore prove to be effective in attacking some of the most lethal types of cancer.